Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Higher mortality of hospitalized haematologic patients with COVID-19 compared to non-haematologic is driven by thrombotic complications and development of ARDS: An age-matched cohorts study

Fernández-Cruz et al., Clinical Infection in Practice, doi:10.1016/j.clinpr.2022.100137
Jan 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 27% Improvement Relative Risk HCQ  Fernández-Cruz et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 71 patients in Spain (March - May 2020) Lower mortality with HCQ (not stat. sig., p=0.47) c19hcq.org Fernández-Cruz et al., Clinical Infect.., Jan 2022 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19hcq.org
Retrospective 71 hospitalized haematologic patients in Spain, showing lower mortality with HCQ treatment in unadjusted results and without statistical significance.
Although the 27% lower mortality is not statistically significant, it is consistent with the significant 26% lower mortality [22‑30%] from meta analysis of the 250 mortality results to date.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 27.0% lower, RR 0.73, p = 0.47, treatment 23 of 63 (36.5%), control 4 of 8 (50.0%), NNT 7.4.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Fernández-Cruz et al., 31 Jan 2022, retrospective, Spain, peer-reviewed, 10 authors, study period March 2020 - May 2020. Contact: afcruz@salud.madrid.org.
This PaperHCQAll
Abstract: Clinical Infection in Practice 13 (2022) 100137 Contents lists available at ScienceDirect Clinical Infection in Practice journal homepage: www.sciencedirect.com/journal/clinical-infection-in-practice Case Reports and Series Higher mortality of hospitalized haematologic patients with COVID-19 compared to non-haematologic is driven by thrombotic complications and development of ARDS: An age-matched cohorts study☆ Ana Fernández-Cruz a, g, *, Alba Puyuelo b, Lucía Núñez Martín-Buitrago b, Enrique SánchezChica c, Carmen Díaz-Pedroche d, h, j, Rosa Ayala e, h, Manuel Lizasoain f, h, Rafael Duarte b, g, i, Carlos Lumbreras f, h, j, Juan Antonio Vargas c, g, i a Infectious Diseases Department, Hospital Puerta de Hierro-Majadahonda, Madrid, Spain Haematology Department, Hospital Puerta de Hierro-Majadahonda, Madrid, Spain c Internal Medicine Department, Hospital Puerta de Hierro-Majadahonda, Madrid, Spain d Internal Medicine Department, Hospital Doce de Octubre, Madrid, Spain e Haematology Department, Hospital Doce de Octubre, Madrid, Spain f Infectious Diseases Department, Hospital Doce de Octubre, Madrid, Spain g Fundación de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Spain h Fundación para la Investigación Biomédica del Hospital Universitario, 12 de Octubre, Spain i Universidad Autónoma de Madrid, Spain j Universidad Complutense de Madrid, Spain b A R T I C L E I N F O A B S T R A C T Keywords COVID-19 Haematologic Outcome Mortality Background and Objectives: The characteristics of COVID-19 in haematologic patients compared to nonhaematologic patients have seldom been analyzed. Our aim was to analyze whether there are differences in clinical characteristics and outcome of haematologic patients with COVID-19 as compared to non-haematologic. Patients and methods: Retrospective cohort study in 2 University hospitals of patients admitted with laboratoryconfirmed COVID-19 included in the SEMICOVID19 database. The cohort with underlying haematologic disease was compared to a cohort of age and date-of-COVID-19-matched controls without haematologic disease (1:2). Results: 71 cases and 142 controls were included from March-May 2020. Twenty (28.1%) had received recent chemotherapy. Twelve (16.9%) were stem cell transplant recipients (SCT). Eleven (15.5%) were neutropenic concurrently with COVID-19 diagnosis. Haematologic patients presented ARDS (58.5 vs 20.7%, p = 0.0001), thrombotic complications (15.7 vs 2.1%, p = 0.002), DIC (5.7 vs 0.0%, p = 0.011), heart failure (14.3 vs 4.9%, p = 0.029) and required ICU admission (15.5 vs 2.8%, p = 0.001), MV (14.1% vs 2.1%, p 0.001), steroid (64.8 vs 33.1%, p = 0.0001), tocilizumab (33.8 vs 8.5%, p = 0.0001) or anakinra treatment (9.9% vs 0%, p = 0.0001) more often. In-hospital mortality was significantly higher (38.0% vs 18.3%, p = 0.002). Conclusions: Our results suggest COVID-19 has worse outcomes in haematologic patients than in nonhaematologic, independently of age, and that the development of ARDS and thrombotic complications drive the higher in-hospital mortality. Abbreviations: ARDS, acute respiratory distress syndrome; C-RP, C-reactive protein; CI, confidence interval; CLL, chronic lymphocytic leukemia; COVID-19, Coronavirus disease 2019; DIC, disseminated intravascular coagulation; ECOG scale, Eastern Cooperative Oncology Group scale; G-CSF, granulocyte stimulating factor; HFNC, high flow nasal cannula; ICU, Intensive Care Unit; IL6, Interleukin 6; IQR,..
{ 'indexed': {'date-parts': [[2022, 4, 22]], 'date-time': '2022-04-22T23:41:45Z', 'timestamp': 1650670905449}, 'reference-count': 25, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2022, 1, 1]], 'date-time': '2022-01-01T00:00:00Z', 'timestamp': 1640995200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2022, 2, 10]], 'date-time': '2022-02-10T00:00:00Z', 'timestamp': 1644451200000}, 'content-version': 'vor', 'delay-in-days': 40, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2022, 1]]}, 'DOI': '10.1016/j.clinpr.2022.100137', 'type': 'journal-article', 'created': {'date-parts': [[2022, 2, 15]], 'date-time': '2022-02-15T03:43:08Z', 'timestamp': 1644896588000}, 'page': '100137', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Higher mortality of hospitalized haematologic patients with COVID-19 compared to ' 'non-haematologic is driven by thrombotic complications and development of ARDS: An age-matched ' 'cohorts study', 'prefix': '10.1016', 'volume': '13', 'author': [ {'given': 'Ana', 'family': 'Fernández-Cruz', 'sequence': 'first', 'affiliation': []}, {'given': 'Alba', 'family': 'Puyuelo', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Lucía', 'family': 'Núñez Martín-Buitrago', 'sequence': 'additional', 'affiliation': []}, {'given': 'Enrique', 'family': 'Sánchez-Chica', 'sequence': 'additional', 'affiliation': []}, {'given': 'Carmen', 'family': 'Díaz-Pedroche', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rosa', 'family': 'Ayala', 'sequence': 'additional', 'affiliation': []}, {'given': 'Manuel', 'family': 'Lizasoain', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rafael', 'family': 'Duarte', 'sequence': 'additional', 'affiliation': []}, {'given': 'Carlos', 'family': 'Lumbreras', 'sequence': 'additional', 'affiliation': []}, {'given': 'Juan', 'family': 'Antonio Vargas', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'issue': '3', 'key': '10.1016/j.clinpr.2022.100137_b0005', 'doi-asserted-by': 'crossref', 'first-page': '542', 'DOI': '10.1016/j.bbmt.2015.11.015', 'article-title': 'Outcomes of Influenza Infections in Hematopoietic Cell Transplant ' 'Recipients: Application of an Immunodeficiency Scoring Index', 'volume': '22', 'author': 'Kmeid', 'year': '2016', 'journal-title': 'Biol Blood Marrow Transplant'}, { 'issue': '4', 'key': '10.1016/j.clinpr.2022.100137_b0010', 'doi-asserted-by': 'crossref', 'DOI': '10.1111/tid.13105', 'article-title': 'Refinement of estimates of mortality risk using the Radiologic Severity ' 'Index in hematologic malignancy patients with respiratory syncytial ' 'virus infection', 'volume': '21', 'author': 'Sheshadri', 'year': '2019', 'journal-title': 'Transpl Infect Dis'}, { 'issue': '2', 'key': '10.1016/j.clinpr.2022.100137_b0015', 'doi-asserted-by': 'crossref', 'first-page': '351', 'DOI': '10.1093/cid/ciaa1079', 'article-title': 'Are All Patients with Cancer at Heightened Risk for Severe Coronavirus ' 'Disease 2019 (COVID-19)?', 'volume': '72', 'author': 'Chamilos', 'year': '2021', 'journal-title': 'Clin Infect Dis'}, { 'issue': '1', 'key': '10.1016/j.clinpr.2022.100137_b0020', 'doi-asserted-by': 'crossref', 'DOI': '10.1186/s13045-020-00970-7', 'article-title': 'Impact of hematologic malignancy and type of cancer therapy on COVID-19 ' 'severity and mortality: lessons from a large population-based registry ' 'study', 'volume': '13', 'author': 'García-Suárez', 'year': '2020', 'journal-title': 'J Hematol Oncol'}, { 'issue': '10', 'key': '10.1016/j.clinpr.2022.100137_b0025', 'doi-asserted-by': 'crossref', 'first-page': 'e737', 'DOI': '10.1016/S2352-3026(20)30251-9', 'article-title': 'Clinical characteristics and risk factors associated with COVID-19 ' 'severity in patients with haematological malignancies in Italy: a ' 'retrospective, multicentre, cohort study', 'volume': '7', 'author': 'Passamonti', 'year': '2020', 'journal-title': 'Lancet Haematol'}, { 'issue': '8', 'key': '10.1016/j.clinpr.2022.100137_b0030', 'doi-asserted-by': 'crossref', 'first-page': '480', 'DOI': '10.1016/j.rce.2020.07.003', 'article-title': 'Clinical characteristics of patients hospitalized with COVID-19 in ' 'Spain: Results from the SEMI-COVID-19 Registry', 'volume': '220', 'author': 'Casas-Rojo', 'year': '2020', 'journal-title': 'Rev Clin Esp'}, { 'issue': '4', 'key': '10.1016/j.clinpr.2022.100137_b0035', 'doi-asserted-by': 'crossref', 'first-page': '424', 'DOI': '10.1182/blood-2016-08-733196', 'article-title': 'Diagnosis and management of AML in adults: 2017 ELN recommendations ' 'from an international expert panel', 'volume': '129', 'author': 'Döhner', 'year': '2017', 'journal-title': 'Blood'}, { 'issue': '27', 'key': '10.1016/j.clinpr.2022.100137_b0040', 'doi-asserted-by': 'crossref', 'first-page': '3059', 'DOI': '10.1200/JCO.2013.54.8800', 'article-title': 'Recommendations for initial evaluation, staging, and response ' 'assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano ' 'classification', 'volume': '32', 'author': 'Cheson', 'year': '2014', 'journal-title': 'J Clin Oncol'}, { 'issue': '8', 'key': '10.1016/j.clinpr.2022.100137_b0045', 'doi-asserted-by': 'crossref', 'first-page': 'e328', 'DOI': '10.1016/S1470-2045(16)30206-6', 'article-title': 'International Myeloma Working Group consensus criteria for response and ' 'minimal residual disease assessment in multiple myeloma', 'volume': '17', 'author': 'Kumar', 'year': '2016', 'journal-title': 'Lancet Oncol'}, { 'issue': '6', 'key': '10.1016/j.clinpr.2022.100137_b0050', 'doi-asserted-by': 'crossref', 'first-page': '649', 'DOI': '10.1097/00000421-198212000-00014', 'article-title': 'Toxicity and response criteria of the Eastern Cooperative Oncology ' 'Group', 'volume': '5', 'author': 'Oken', 'year': '1982', 'journal-title': 'AMERICAN JOURNAL OF CLINICAL ONCOLOGY'}, { 'issue': '23', 'key': '10.1016/j.clinpr.2022.100137_b0055', 'first-page': '2526', 'article-title': 'Acute respiratory distress syndrome: the Berlin Definition', 'volume': '307', 'author': 'Force', 'year': '2012', 'journal-title': 'JAMA'}, { 'issue': '16', 'key': '10.1016/j.clinpr.2022.100137_b0060', 'doi-asserted-by': 'crossref', 'first-page': 'e25634', 'DOI': '10.1097/MD.0000000000025634', 'article-title': 'Major determinants of death in patients hospitalized with COVID-19 ' 'during the first epidemic wave in Madrid, Spain', 'volume': '100', 'author': 'Moreno-Torres', 'year': '2021', 'journal-title': 'Medicine (Baltimore)'}, { 'issue': '6', 'key': '10.1016/j.clinpr.2022.100137_b0065', 'doi-asserted-by': 'crossref', 'first-page': '622', 'DOI': '10.1016/S2213-2600(21)00218-6', 'article-title': 'The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a ' 'new disease entity', 'volume': '9', 'author': 'Osuchowski', 'year': '2021', 'journal-title': 'Lancet Respir Med'}, { 'issue': '6', 'key': '10.1016/j.clinpr.2022.100137_b0070', 'doi-asserted-by': 'crossref', 'first-page': 'R173', 'DOI': '10.1186/cc8149', 'article-title': 'Risk factors for acute respiratory distress syndrome during neutropenia ' 'recovery in patients with hematologic malignancies', 'volume': '13', 'author': 'Rhee', 'year': '2009', 'journal-title': 'Crit Care'}, { 'issue': '4', 'key': '10.1016/j.clinpr.2022.100137_b0075', 'doi-asserted-by': 'crossref', 'DOI': '10.1111/tid.13606', 'article-title': 'Immune reconstitution and severity of COVID‐19 among hematopoietic cell ' 'transplant recipients', 'volume': '23', 'author': 'Malek', 'year': '2021', 'journal-title': 'Transpl Infect Dis'}, { 'issue': '5', 'key': '10.1016/j.clinpr.2022.100137_b0080', 'doi-asserted-by': 'crossref', 'first-page': '1156', 'DOI': '10.1080/10428194.2018.1516874', 'article-title': 'Granulocyte colony-stimulating factor and respiratory status of ' 'critically ill neutropenic patients with hematologic malignancies', 'volume': '60', 'author': 'Mignard', 'year': '2019', 'journal-title': 'Leuk Lymphoma'}, { 'issue': '5', 'key': '10.1016/j.clinpr.2022.100137_b0085', 'doi-asserted-by': 'crossref', 'first-page': '319', 'DOI': '10.1038/s41577-021-00536-9', 'article-title': 'Endothelial dysfunction and immunothrombosis as key pathogenic ' 'mechanisms in COVID-19', 'volume': '21', 'author': 'Bonaventura', 'year': '2021', 'journal-title': 'Nat Rev Immunol'}, { 'issue': '8', 'key': '10.1016/j.clinpr.2022.100137_b0090', 'doi-asserted-by': 'crossref', 'first-page': '899', 'DOI': '10.1007/s00134-021-06419-w', 'article-title': 'Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis', 'volume': '47', 'author': "O'Donnell", 'year': '2021', 'journal-title': 'Intensive Care Med'}, { 'key': '10.1016/j.clinpr.2022.100137_b0095', 'doi-asserted-by': 'crossref', 'first-page': '24', 'DOI': '10.1016/j.blre.2018.06.002', 'article-title': 'Venous thromboembolism incidence in hematologic malignancies', 'volume': '33', 'author': 'Kekre', 'year': '2019', 'journal-title': 'Blood Rev'}, { 'key': '10.1016/j.clinpr.2022.100137_b0100', 'doi-asserted-by': 'crossref', 'first-page': '202', 'DOI': '10.1016/j.jhin.2021.02.014', 'article-title': 'Duration of isolation and precautions in immunocompromised patients ' 'with COVID-19', 'volume': '111', 'author': 'Taramasso', 'year': '2021', 'journal-title': 'J Hosp Infect'}, { 'issue': '1', 'key': '10.1016/j.clinpr.2022.100137_b0105', 'doi-asserted-by': 'crossref', 'DOI': '10.1186/s40164-020-00177-z', 'article-title': 'Risk factors and outcome of COVID-19 in patients with hematological ' 'malignancies', 'volume': '9', 'author': 'Piñana', 'year': '2020', 'journal-title': 'Exp Hematol Oncol'}, { 'issue': '1', 'key': '10.1016/j.clinpr.2022.100137_b0110', 'doi-asserted-by': 'crossref', 'DOI': '10.1111/tid.13401', 'article-title': 'Severe COVID-19 in a patient with chronic graft-versus-host disease ' 'after hematopoietic stem cell transplant successfully treated with ' 'ruxolitinib', 'volume': '23', 'author': 'Saraceni', 'year': '2021', 'journal-title': 'Transpl Infect Dis'}, { 'key': '10.1016/j.clinpr.2022.100137_b0115', 'doi-asserted-by': 'crossref', 'first-page': '100755', 'DOI': '10.1016/j.cegh.2021.100755', 'article-title': 'The use of Janus Kinase inhibitors in hospitalized patients with ' 'COVID-19: Systematic review and meta-analysis', 'volume': '11', 'author': 'Wijaya', 'year': '2021', 'journal-title': 'Clin Epidemiol Glob Health'}, { 'key': '10.1016/j.clinpr.2022.100137_b0120', 'article-title': 'BTK inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 ' '(SARS-CoV-2): A Systematic Review', 'author': 'Stack', 'year': '2021', 'journal-title': 'Res Sq'}, { 'key': '10.1016/j.clinpr.2022.100137_b0125', 'doi-asserted-by': 'crossref', 'first-page': '154', 'DOI': '10.1016/j.ejca.2021.01.033', 'article-title': '2021 update of the AGIHO guideline on evidence-based management of ' 'COVID-19 in patients with cancer regarding diagnostics, viral shedding, ' 'vaccination and therapy', 'volume': '147', 'author': 'Giesen', 'year': '2021', 'journal-title': 'Eur J Cancer'}], 'container-title': 'Clinical Infection in Practice', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S259017022200005X?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S259017022200005X?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2022, 4, 22]], 'date-time': '2022-04-22T23:04:49Z', 'timestamp': 1650668689000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S259017022200005X'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 1]]}, 'references-count': 25, 'alternative-id': ['S259017022200005X'], 'URL': 'http://dx.doi.org/10.1016/j.clinpr.2022.100137', 'relation': {}, 'ISSN': ['2590-1702'], 'subject': ['General Medicine'], 'container-title-short': 'Clinical Infection in Practice', 'published': {'date-parts': [[2022, 1]]}, 'article-number': '100137'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit